IS8293A - Pýrról-2,5-díónafleiður sem viðtakastillar lifrarX - Google Patents
Pýrról-2,5-díónafleiður sem viðtakastillar lifrarXInfo
- Publication number
- IS8293A IS8293A IS8293A IS8293A IS8293A IS 8293 A IS8293 A IS 8293A IS 8293 A IS8293 A IS 8293A IS 8293 A IS8293 A IS 8293A IS 8293 A IS8293 A IS 8293A
- Authority
- IS
- Iceland
- Prior art keywords
- pyrrole
- dione derivatives
- liver receptor
- regulate liver
- regulate
- Prior art date
Links
- PEEHTFAAVSWFBL-UHFFFAOYSA-N Maleimide Chemical class O=C1NC(=O)C=C1 PEEHTFAAVSWFBL-UHFFFAOYSA-N 0.000 title 1
- 210000004185 liver Anatomy 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/44—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having three double bonds between ring members or between ring members and non-ring members
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/44—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having three double bonds between ring members or between ring members and non-ring members
- C07D207/444—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having three double bonds between ring members or between ring members and non-ring members having two doubly-bound oxygen atoms directly attached in positions 2 and 5
- C07D207/456—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having three double bonds between ring members or between ring members and non-ring members having two doubly-bound oxygen atoms directly attached in positions 2 and 5 with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to other ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Heart & Thoracic Surgery (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Cardiology (AREA)
- Emergency Medicine (AREA)
- Child & Adolescent Psychology (AREA)
- Vascular Medicine (AREA)
- Hospice & Palliative Care (AREA)
- Urology & Nephrology (AREA)
- Endocrinology (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Pyrrole Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB0316232.8A GB0316232D0 (en) | 2003-07-11 | 2003-07-11 | Therapeutic agents |
PCT/SE2004/001114 WO2005005417A1 (en) | 2003-07-11 | 2004-07-08 | Pyrrole-2, 5-dione derivatives as liver x receptor modulators |
Publications (1)
Publication Number | Publication Date |
---|---|
IS8293A true IS8293A (is) | 2006-02-09 |
Family
ID=27741983
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
IS8293A IS8293A (is) | 2003-07-11 | 2006-02-09 | Pýrról-2,5-díónafleiður sem viðtakastillar lifrarX |
Country Status (26)
Country | Link |
---|---|
US (1) | US7432288B2 (is) |
EP (1) | EP1646626B1 (is) |
JP (1) | JP2007521312A (is) |
KR (1) | KR20060035748A (is) |
CN (1) | CN1823061A (is) |
AR (1) | AR045721A1 (is) |
AT (1) | ATE399777T1 (is) |
AU (1) | AU2004255999B2 (is) |
BR (1) | BRPI0412472A (is) |
CA (1) | CA2532056A1 (is) |
DE (1) | DE602004014773D1 (is) |
ES (1) | ES2308204T3 (is) |
GB (1) | GB0316232D0 (is) |
HK (1) | HK1088320A1 (is) |
IL (1) | IL172760A0 (is) |
IS (1) | IS8293A (is) |
MX (1) | MXPA06000414A (is) |
MY (1) | MY135821A (is) |
NO (1) | NO20060081L (is) |
RU (1) | RU2006102130A (is) |
SA (1) | SA04250204B1 (is) |
TW (1) | TW200503691A (is) |
UA (1) | UA82109C2 (is) |
UY (1) | UY28408A1 (is) |
WO (1) | WO2005005417A1 (is) |
ZA (1) | ZA200600222B (is) |
Families Citing this family (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1634877B1 (en) * | 2004-08-17 | 2011-06-22 | Simpson Biotech Co., Ltd. | Mixture and compounds from mycelia of antrodia camphorata and use thereof |
US7505238B2 (en) * | 2005-01-07 | 2009-03-17 | Agnes Neves Woo | ESD configuration for low parasitic capacitance I/O |
SE0500055D0 (sv) | 2005-01-10 | 2005-01-10 | Astrazeneca Ab | Therapeutic agents 3 |
EP1838686A4 (en) | 2005-01-10 | 2010-02-24 | Astrazeneca Ab | ISOTHIAZOL-3 (2H) -ONE 1,1-DIOXIDE DERIVATIVES AS LIVER X-RECEPTOR MODULATORS |
EP2029536B1 (en) * | 2006-04-28 | 2013-08-28 | Laboratorios Del. Dr. Esteve, S.A. | Bicyclic tetrahydropyrrole compounds |
AU2007286807B2 (en) | 2006-08-21 | 2013-03-21 | Genentech, Inc. | Aza-benzothiophenyl compounds and methods of use |
CN101456863B (zh) * | 2007-12-14 | 2012-04-25 | 华北制药集团新药研究开发有限责任公司 | Lxr激动剂及其制备方法和用途 |
CA2727252A1 (en) | 2008-07-01 | 2010-01-07 | Genentech, Inc. | Isoindolone derivatives as mek kinase inhibitors and methods of use |
AU2009266956B2 (en) | 2008-07-01 | 2014-03-20 | Genentech, Inc. | Bicyclic heterocycles as MEK kinase inhibitors |
US20130274212A1 (en) | 2010-09-07 | 2013-10-17 | Snu R&Db Foundation | Sesterterpene Compounds and Use Thereof |
EP2646018B1 (en) | 2010-12-03 | 2014-10-22 | Allergan, Inc. | Novel oxime azetidine derivatives as sphingosine 1-phosphate (s1p) receptor modulators |
KR20130127479A (ko) | 2010-12-03 | 2013-11-22 | 알러간, 인코포레이티드 | 스핑고신 1-포스페이트 (s1p) 수용체 조절제로서의 신규한 옥심 유도체 |
US10669296B2 (en) | 2014-01-10 | 2020-06-02 | Rgenix, Inc. | LXR agonists and uses thereof |
WO2017123568A2 (en) | 2016-01-11 | 2017-07-20 | The Rockefeller University | Methods for the treatment of myeloid derived suppressor cells related disorders |
US11214536B2 (en) | 2017-11-21 | 2022-01-04 | Inspirna, Inc. | Polymorphs and uses thereof |
US11174220B2 (en) | 2019-12-13 | 2021-11-16 | Inspirna, Inc. | Metal salts and uses thereof |
WO2022109066A1 (en) * | 2020-11-18 | 2022-05-27 | Southern Research Institute | Compounds for the treatment of acute and chronic kidney disease |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ID27510A (id) | 1998-07-30 | 2001-04-12 | Japan Tobacco Inc | Senyawa malimida tersubstitusi dan penggunaan farmasinya |
EP1119548B1 (en) * | 1998-10-08 | 2004-12-08 | SmithKline Beecham plc | 3-(3-chloro-4-hydroxyphenylamino)-4-(2-nitrophenyl)-1h-pyrrole-2,5-dione as glycogen synthase kinase-3 inhibitor (gsk-3) |
JP2004500332A (ja) * | 1999-07-08 | 2004-01-08 | テュラリク インコーポレイテッド | Hdlコレステロール値を上昇させる組成物および方法 |
WO2001013916A1 (fr) | 1999-08-20 | 2001-03-01 | Sagami Chemical Research Center | Medicaments inhibant la mort cellulaire |
GB0008264D0 (en) | 2000-04-04 | 2000-05-24 | Smithkline Beecham Plc | Novel method and compounds |
-
2003
- 2003-07-11 GB GBGB0316232.8A patent/GB0316232D0/en not_active Ceased
-
2004
- 2004-06-29 TW TW093119064A patent/TW200503691A/zh unknown
- 2004-07-05 SA SA4250204A patent/SA04250204B1/ar unknown
- 2004-07-08 DE DE602004014773T patent/DE602004014773D1/de not_active Expired - Fee Related
- 2004-07-08 RU RU2006102130/04A patent/RU2006102130A/ru not_active Application Discontinuation
- 2004-07-08 ES ES04749150T patent/ES2308204T3/es not_active Expired - Lifetime
- 2004-07-08 JP JP2006520138A patent/JP2007521312A/ja not_active Withdrawn
- 2004-07-08 AT AT04749150T patent/ATE399777T1/de not_active IP Right Cessation
- 2004-07-08 CA CA002532056A patent/CA2532056A1/en not_active Abandoned
- 2004-07-08 MX MXPA06000414A patent/MXPA06000414A/es not_active Application Discontinuation
- 2004-07-08 KR KR1020067000712A patent/KR20060035748A/ko not_active Withdrawn
- 2004-07-08 AR ARP040102419A patent/AR045721A1/es not_active Application Discontinuation
- 2004-07-08 AU AU2004255999A patent/AU2004255999B2/en not_active Ceased
- 2004-07-08 WO PCT/SE2004/001114 patent/WO2005005417A1/en active IP Right Grant
- 2004-07-08 EP EP04749150A patent/EP1646626B1/en not_active Expired - Lifetime
- 2004-07-08 CN CNA2004800198411A patent/CN1823061A/zh active Pending
- 2004-07-08 US US10/564,235 patent/US7432288B2/en not_active Expired - Fee Related
- 2004-07-08 BR BRPI0412472-3A patent/BRPI0412472A/pt not_active IP Right Cessation
- 2004-07-09 MY MYPI20042745A patent/MY135821A/en unknown
- 2004-07-09 UY UY28408A patent/UY28408A1/es unknown
- 2004-08-07 UA UAA200600272A patent/UA82109C2/uk unknown
-
2005
- 2005-12-22 IL IL172760A patent/IL172760A0/en unknown
-
2006
- 2006-01-05 NO NO20060081A patent/NO20060081L/no not_active Application Discontinuation
- 2006-01-10 ZA ZA200600222A patent/ZA200600222B/en unknown
- 2006-02-09 IS IS8293A patent/IS8293A/is unknown
- 2006-08-08 HK HK06108803.4A patent/HK1088320A1/xx not_active IP Right Cessation
Also Published As
Publication number | Publication date |
---|---|
AU2004255999B2 (en) | 2007-08-02 |
HK1088320A1 (en) | 2006-11-03 |
EP1646626A1 (en) | 2006-04-19 |
MY135821A (en) | 2008-07-31 |
TW200503691A (en) | 2005-02-01 |
NO20060081L (no) | 2006-02-08 |
CA2532056A1 (en) | 2005-01-20 |
GB0316232D0 (en) | 2003-08-13 |
KR20060035748A (ko) | 2006-04-26 |
ZA200600222B (en) | 2007-04-25 |
CN1823061A (zh) | 2006-08-23 |
SA04250204B1 (ar) | 2008-03-23 |
ATE399777T1 (de) | 2008-07-15 |
UA82109C2 (uk) | 2008-03-11 |
AU2004255999A1 (en) | 2005-01-20 |
WO2005005417A1 (en) | 2005-01-20 |
BRPI0412472A (pt) | 2006-09-19 |
JP2007521312A (ja) | 2007-08-02 |
US7432288B2 (en) | 2008-10-07 |
DE602004014773D1 (de) | 2008-08-14 |
UY28408A1 (es) | 2005-02-28 |
US20060235015A1 (en) | 2006-10-19 |
IL172760A0 (en) | 2006-04-10 |
RU2006102130A (ru) | 2007-08-20 |
MXPA06000414A (es) | 2006-03-17 |
ES2308204T3 (es) | 2008-12-01 |
AR045721A1 (es) | 2005-11-09 |
EP1646626B1 (en) | 2008-07-02 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IS8293A (is) | Pýrról-2,5-díónafleiður sem viðtakastillar lifrarX | |
IS8291A (is) | Pýrról-2,5-tvíþíónafleiður sem lifrar X viðtakastillar | |
ZA200606974B (en) | Substituted 1,2,3,4-tetrahydrolsoquinoline derivatives | |
IS8466A (is) | 3-Sýklóalkýlamínópýrrólidín afleiður sem stillar á flakkboða viðtaka | |
HK1209729A1 (en) | Compounds, compositions and methods | |
HK1090635A1 (en) | Substituted 3-sulfur indoles | |
ZA200702479B (en) | 4-heteroarylmethyl substituted phthalazinone derivatives | |
IL181408A0 (en) | 4-heteroarylmethyl substituted phthalazinone derivatives | |
ATE440085T1 (de) | 3-substituierte 1,5-diphenylpyrazolderivate, die sich als cb1-modulatoren eignen | |
DK1824856T3 (da) | 2,4 (4,6)-pyrimidinderivater | |
ZA200700159B (en) | Phenyl substituted [1.2]-oxazine-3,5-dione and dihydropyrone derivatives | |
IL183594A0 (en) | Phenyl-piperazin methanone derivatives | |
DE502005007723D1 (de) | 18-methyl-19-nor-17-pregn-4-en-21,17-carbolactone, | |
IS8278A (is) | Sýkóprópýl afleiður sem NK3 viðtaka mótlyf | |
EP1811842A4 (en) | IMMUNE ACTIVATION COMPOSITIONS BASED ON 3,3'-DIINDOLYLMETHANE | |
BRPI0509256A (pt) | derivados de pirrolidina-3,4-dicarboxamida | |
DE502005000496D1 (de) | Verstellvorrichtung | |
ES1058958Y (es) | Mastil perfeccionado. | |
EP1711189A4 (en) | AZALIDE DERIVATIVES 8A 6,11-3C-BICYCLIC | |
ES1058483Y (es) | Bloque de asientos perfeccionado. | |
ES1057238Y (es) | Buzon perfeccionado. | |
ITRM20040370A1 (it) | Chiusino perfezionato. | |
GB0413742D0 (en) | Cross-cut router attachment | |
ES1058233Y (es) | Cambrillon perfeccionado. | |
ES1057931Y (es) | Sacacorchos de palanca perfeccionado. |